Stephen R. Saklad, Pharm.D., BCCP, FAAPP

The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.

Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discussed the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective vesicular monoamine transporter 2 (VMAT2) inhibitor treatments have only been available since 2017.